DR. PETER NICHOLAS KAO, M.D.
Osteopathic Medicine at Pasteur Dr, Palo Alto, CA
License number
California G067731
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
300 Pasteur Dr, Palo Alto, CA 94305
Phone
(650) 723-6381
Professional information
Dr. Peter N Kao, Palo Alto CA - MD (Doctor of Medicine)
Specialties:
Critical Care Medicine, Pulmonology
Address:
300 Pasteur Dr STE H3143, Palo Alto 94304
(650) 723-6381 (Phone)
Stanford University Medical Center PUL
300 Pasteur Dr STE H3143, Stanford 94305
(650) 725-7061 (Phone)
(650) 723-6381 (Phone)
Stanford University Medical Center PUL
300 Pasteur Dr STE H3143, Stanford 94305
(650) 725-7061 (Phone)
Certifications:
Critical Care Medicine, 2000, Internal Medicine, 1991, Pulmonary Disease, 2000
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
300 Pasteur Dr STE H3143, Palo Alto 94304
Stanford University Medical Center PUL
300 Pasteur Dr STE H3143, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Stanford University Medical Center PUL
300 Pasteur Dr STE H3143, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Education:
Medical School
Columbia University College Of Physicians and Surgeons
Graduated: 1988
Stanford University Hospital
Graduated: 1989
Graduated: 1993
Graduated: 1994
Columbia University College Of Physicians and Surgeons
Graduated: 1988
Stanford University Hospital
Graduated: 1989
Graduated: 1993
Graduated: 1994
Peter Nicholas Kao, Stanford CA
Specialties:
Internist
Address:
300 Pasteur Dr, Stanford, CA 94305
Education:
Columbia University, College of Physicians and Surgeons - Doctor of Medicine
Stanford Hospital & Clinics - Fellowship - Pulmonary Disease (Internal Medicine)
Stanford Hospital & Clinics - Residency - Internal Medicine
Stanford Hospital & Clinics - Fellowship - Pulmonary Disease (Internal Medicine)
Stanford Hospital & Clinics - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Critical Care Medicine (Internal Medicine), American Board of Internal Medicine Sub-certificate in Pulmonary Disease (Internal Medicine)
Peter Nicholas Kao, Palo Alto CA
Specialties:
Internal Medicine, Critical Care Medicine, Pulmonary Disease
Work:
Stanford Hospital and Clinics
300 Pasteur Dr, Palo Alto, CA 94304 Stanford University
300 Pasteur Dr, Stanford, CA 94305
300 Pasteur Dr, Palo Alto, CA 94304 Stanford University
300 Pasteur Dr, Stanford, CA 94305
Education:
Columbia University (1988)
Use Of Antiproliferative Agents In The Treatment And Prevention Of Pulmonary Proliferative Vascular Diseases
US Patent:
2005011, Jun 2, 2005
Filed:
Mar 15, 2004
Appl. No.:
10/801729
Inventors:
Peter Kao - Palo Alto CA, US
Ronald Pearl - Palo Alto CA, US
Toshihiko Nishimura - Menlo Park CA, US
John Faul - Stanford CA, US
Ronald Pearl - Palo Alto CA, US
Toshihiko Nishimura - Menlo Park CA, US
John Faul - Stanford CA, US
International Classification:
A61K031/401, A61K031/366, A61K031/255
US Classification:
514423000, 514460000, 514548000
Abstract:
Methods of treating lung proliferative vascular disorders by administering an antiproliferative agent are provided. A preferred antiproliferative agent is a HMG-CoA reductase inhibitor, preferably simvastatin. Vascular occlusion in the pulmonary arteries of the patient is reduced as a result of the treatment through a reduction in neointimal hyperplasia and medial hypertrophy, and the restoration of normal endothelial cell function. The treatment also results in a reversal of right side cardiac hypertrophy. Lung proliferative vascular disorders that can be treated include primary pulmonary hypertension, secondary pulmonary hypertension, Eisenmenger's syndrome, chronic thromboembolic disease, pulmonary fibrosis, obliterative bronchiolitis, or lymphangioleiomyomatosis. Dosages and pharmaceutical formulations are provided.
Implantable Arterio-Venous Shunt Devices And Methods For Their Use
US Patent:
7628768, Dec 8, 2009
Filed:
Oct 7, 2004
Appl. No.:
10/961731
Inventors:
John L. Faul - Stanford CA, US
Toshihiko Nishimura - Menlo Park CA, US
Peter N. Kao - Palo Alto CA, US
Ronald G. Pearl - Palo Alto CA, US
Toshihiko Nishimura - Menlo Park CA, US
Peter N. Kao - Palo Alto CA, US
Ronald G. Pearl - Palo Alto CA, US
Assignee:
Rox Medical, Inc. - San Clemente CA
International Classification:
A61M 19/00
US Classification:
604 8, 604264
Abstract:
A long-term implantable arterio-venous shunt device is provided that can be used as a therapeutic method. The shunt device is implanted between an artery and a vein, preferably between the aorta and the inferior vena cava. The shunt device decreases the systemic vascular resistance and allows a blood flow rate through the shunt device of at least 5 ml/min after the implantation. The blood flow rate could be controlled either via an open loop or a closed loop control means. The shunt device could also be a self-adjustable shunt device to self-adjust its structure to control the blood flow rate through its lumen. Based on the effects of the shunt device to the respiratory, cardiac and circulatory system, the implantable shunt device could be beneficial as a therapy to patients with problems or conditions related to these systems.
Arterio-Venous Shunt Devices
US Patent:
8048016, Nov 1, 2011
Filed:
Feb 12, 2009
Appl. No.:
12/378438
Inventors:
John L. Faul - Stanford CA, US
Toshihiko Nishimura - Menlo Park CA, US
Peter N. Kao - Palo Alto CA, US
Ronald G. Pearl - Palo Alto CA, US
Toshihiko Nishimura - Menlo Park CA, US
Peter N. Kao - Palo Alto CA, US
Ronald G. Pearl - Palo Alto CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
A61M 19/00
US Classification:
604 8, 604264
Abstract:
A long-term implantable arterio-venous shunt device is provided that can be used as a therapeutic method. The shunt device is implanted between an artery and a vein, preferably between the aorta and the inferior vena cava. The shunt device decreases the systemic vascular resistance and allows a blood flow rate through the shunt device of at least 5 ml/min after the implantation. The blood flow rate could be controlled either via an open loop or a closed loop control means. The shunt device could also be a self-adjustable shunt device to self-adjust its structure to control the blood flow rate through its lumen. Based on the effects of the shunt device to the respiratory, cardiac and circulatory system, the implantable shunt device could be beneficial as a therapy to patients with problems or conditions related to these systems.
Implantable Arteriovenous Shunt Device
US Patent:
2004024, Dec 9, 2004
Filed:
Apr 6, 2004
Appl. No.:
10/820169
Inventors:
John Faul - Stanford CA, US
Toshihiko Nishimura - Menlo Park CA, US
Peter Kao - Palo Alto CA, US
Ronald Pearl - Palo Alto CA, US
Toshihiko Nishimura - Menlo Park CA, US
Peter Kao - Palo Alto CA, US
Ronald Pearl - Palo Alto CA, US
International Classification:
A61F002/06
US Classification:
604/009000, 623/001240
Abstract:
A long-term implantable arteriovenous shunt device is provided that can be used as a therapeutic method. The shunt device is implanted between an artery and a vein, preferably between the aorta and the inferior vena cava. The shunt device decreases the systemic vascular resistance and allows a blood flow rate through the shunt device of at least 5 ml/min after the implantation. The blood flow rate could be controlled either via an open loop or a closed loop control means. The shunt device could also be a self-adjustable shunt device to self-adjust its structure to control the blood flow rate through its lumen. Based on the effects of the shunt device to the respiratory, cardiac and circulatory system, the implantable shunt device could be beneficial as a therapy to patients with problems or conditions related to these systems.
Long-Term Implantable Arterio-Venous Shunt Device
US Patent:
2012001, Jan 12, 2012
Filed:
Sep 23, 2011
Appl. No.:
13/241497
Inventors:
John Faul - Calle lglesia CA, US
Toshihiko Nishimura - San Clemente CA, US
Peter Kao - Stanford CA, US
Ronald Pearl - San Clemente CA, US
Toshihiko Nishimura - San Clemente CA, US
Peter Kao - Stanford CA, US
Ronald Pearl - San Clemente CA, US
International Classification:
A61M 1/00
US Classification:
604 9, 604 8
Abstract:
A long-term implantable arterio-venous shunt device is provided that can be used as a therapeutic method. The shunt device is implanted between an artery and a vein, preferably between the aorta and the inferior vena cava. The shunt device decreases the systemic vascular resistance and allows a blood flow rate through the shunt device of at least 5 ml/min after the implantation. The blood flow rate could be controlled either via an open loop or a closed loop control means. The shunt device could also be a self-adjustable shunt device to self-adjust its structure to control the blood flow rate through its lumen. Based on the effects of the shunt device to the respiratory, cardiac and circulatory system, the implantable shunt device could be beneficial as a therapy to patients with problems or conditions related to these systems.
Combined Therapy Of Diterpenoid Triepoxides And Death Domain Receptor Ligands For Synergistic Killing Of Tumor Cells
US Patent:
6329148, Dec 11, 2001
Filed:
Feb 15, 2000
Appl. No.:
9/505250
Inventors:
Glenn D. Rosen - Stanford CA
Peter Kao - Stanford CA
Peter Kao - Stanford CA
Assignee:
The Board of Trustees of the Leland Stanford University - Palo Alto CA
International Classification:
C12Q 168, A01N 6500, A61K 4800
US Classification:
435 6
Abstract:
A synergistic combination of ligands that interact with death domain receptors, and diterpenoid triepoxides is used to increase tumor cell killing by induction of apoptosis. Ligands useful in the invention include TRAIL, TNF-. alpha. , analogs thereof, stabilized multimers thereof, mimetics, etc. Of particular interest are combined therapy with the diterpenoid triepoxides triptolide and derivatives and analogs thereof.